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Abstract 
AIM: This study aims to investigate the effect of ATP, EGF and combination of those two to the Natrium Iodide 
Symporter (NIS) expression in MCF7, SKBR3 and HaCaT cell lines. 
METHODS: MCF7, SKBR3 and HaCaT cell lines were treated with ATP, EGF and combination of those two for 6, 
12 and 24 hours. The expression of NIS mRNA was measured through quantitative-reverse transcription-
polymerase chain reaction (qRT-PCR). The NIS protein expression was confirmed by immunocytofluorescence. 
RESULTS: NIS mRNA was expressed in SKBR3 and HaCaT cell lines but not in MCF7. The levels of NIS mRNA 
expression, after treatment by epidermal growth factor (EGF), adenosine Tri-Phosphate (ATP) or the combination 
of both for 6 and 12 hours were not significantly different from those of untreated cells. However, the treatment by 
a combination of ATP and EGF for 24 hours increases the level of NIS mRNA expression by 1.6 fold higher than 
that of the untreated cells (1.6241 ± 0.3, p < 0.05) and protein NIS expression increase significantly by the 
treatment than untreated cells (P < 0.05). 
CONCLUSION: The level of NIS expression varies among the different subtypes of breast cancer cell lines. 
MCF7 cell line is representing the luminal A subtype of breast cancer does not express NIS. Only SKBR3 cell line 
express NIS and this subtype might be suitable to receive radioiodine therapy as those cells expressing NIS. A 
combination treatment of EGF and ATP increases the expression of NIS mRNA and protein at the membrane in 
SKBR3 cells. 
 
 
 
 
 
Introduction 
 
Natrium Iodide Symporter is a plasma 
membrane glycoprotein. It transports two ions of 
sodium (Na
+
) and one of iodide (I
-
) and maintained by 
Na
+
/K
+
 ATPase [1], [2], [3]. In thyroid cells, NIS plays 
a pivotal role to accumulate iodine. Additionally, NIS is 
also expressed in breast cancer tissue and has been 
considered as a potential target for radioiodine 
therapy. However, NIS expression in breast cancer 
tissues had been reported to be varied between 
studies. 
Furthermore, the molecular mechanism of 
NIS expression in breast cancer remains unclear [4]. 
Interestingly, it has been reported that NIS is highly 
expressed in invasive breast cancer tissues. A study 
by Tazebay et al. reported that indeed, there is a 
correlation between NIS expression and malignant 
transformation of human breast tissue [5], [6]. 
Other than the variation of NIS expression 
level between molecular subtypes of breast cancer, 
the location of NIS expression is another factor that 
may influence the uptake of radioiodine by breast 
cancer cells. Natrium Iodide Symporter supposed to 
be localised at membrane cell instead of in the 
cytoplasm to be fully functional as iodine co-
transporter [7], [8]. Several agents were used to 
increasing NIS expression in breast cancer cells, and 
the effect of those agents had been proven could 
increase radioiodine uptake and cells susceptibility 
toward the treatment. A study reported, EGF 
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increased NIS expression at membrane cell in the 
T47D cell line [9].
 
Another study reported that a 
combination of ATP with all-trans-Retinoid Acid (tRA) 
and hydrocortisone had increased NIS protein 
expression and cell membrane targeting in MCF7 
cells [10]. 
In this study, we examined the effect of EGF 
and ATP for NIS mRNA and protein expressions in 
SKBR3 and MCF7 breast cancer cell lines and HaCaT 
a normal cell line. MCF7 and SKBR3 cell lines are 
representing the luminal A and HER2 type of breast 
cancer, respectively [11]. HaCaT cell line consists of 
normal human keratinocyte cells. It is used as a 
control cell line.  
 
 
Material and Methods 
 
Cell lines and culture conditions 
SKBR3, MCF7 and HaCaT cell lines were 
used in this study. SKBR3 was obtained from the 
American Type Culture Collection (ATCC). MCF7 and 
HaCaT cell lines from faculty of Medicine, Universitas 
Padjadjaran, Bandung-Indonesia. MCF7 and HaCaT 
cells were cultured in RPMI 1640 medium (Sigma-
Aldrich). SKBR3 was cultured in McCoy’s 5A medium 
(Sigma-Aldrich). Both cell culture mediums were 
supplemented with 10% fetal bovine serum (Sigma-
Aldrich), 1% Penicillin, 1% Streptomycin and 1% 
amphotericin B. The cells were incubated at 37
o 
C and 
supplied with 5% of carbon dioxide (CO2) until 80% 
confluence. The cells were incubated in serum-free 
medium overnight and followed by treatment of EGF 
50 ng/ml (Abcam #ab9697), ATP 100M (Sigma-
Aldrich # 1388), and a combination of EGF and ATP, 
for 6, 12 and 24 hours. Each type of cell lines divided 
into four groups based on the type of treatments, such 
as ATP, EGF, combination ATP and EGF groups and 
without any treatment as a control group.  
 
Quantitative real-time reverse 
 transcriptase –PCR (qRT-PCR) 
 The cells were harvested at the appropriate 
time points and then followed by centrifuging at 1000 
rpm for 4 minutes. The total RNA was isolated by 
using the RNeasy mini kit (Qiagen #74106) following 
the manufacturer’s instructions. RNA was quantified 
using Nanodrop 2000, and 5 ng of RNA was reverse 
transcribed and analysed by one-step real-time 
quantitative PCR using Rotor-Gene Quantitect probe 
RT-PCR (Qiagen # 204443) using NIS and beta-actin 
primers. The mRNA NIS expression fold change of 
treated cells to those untreated was analysed using a 
method described by Livak et al., (2
-∆∆C
T) [12]. Three 
independent qPCR assays were conducted in 
triplicate.  
Immunocytofluoresence 
The cells were seeded on coverslips in a well 
of a 24-wells culture plate and fixated by 4% 
paraformaldehyde for 15 minutes. This was followed 
by incubation with protein blocking agent fluorescein-
isothiocyanate (FITC) for 15 minutes. The cells were 
rinsed twice with ice-cold phosphate-buffered saline 
(PBS) and followed by overnight incubation with 
2µg/ml rabbit polyclonal antibody anti-NIS (Abcam, 
#ab83816) at 4°C. The cells were rinsed three times 
with PBS and incubated at room temperature with 
Goat anti-Rabbit IgG secondary polyclonal antibody, 
with dilution 1:1500 (Abcam, #ab6716) for one hour. 
The cells were rinsed three times with PBS. The 
coverslips were placed over slides and mounted with 
fluoroshield containing 4’, 6-diamidino-2-phenylindole 
(DAPI). The slides were inspected under 
immunofluorescence microscope (Olympus BX51) 
with 200 x magnification. Cells that only incubated 
with secondary antibody were used as a negative 
control. 
 
Statistical analysis 
Collected results are expressed as mean  
SD. Responses of treatments to NIS mRNA 
expression were calculated in numeric data. They 
were analysed by ANOVA method to compare means 
between groups and followed by the Turkey test. P < 
0.05 was considered statistically significant when 
compared to controls.  
 NIS protein expression was analysed using 
the Her2/neu category. The results were divided 
based on the level of staining from 0 to 3. Level 0 was 
no staining, 1 was non-complete staining at the 
membrane and pale of > 10% tumour cells, 2 was 
complete staining around the membrane of ≤ 10% 
tumour cells, and 3 was complete staining at 
membrane of > 10% tumour cells. Level 0 and 1 were 
considered as negative, and level 2 to 3 were 
considered as positive [8], [13]. Mann-Whitney test 
was used to compare differences between treatment 
and control groups, P < 0.05 was considered 
statistically significant.  
 
 
Results 
 
Effect of EGF and ATP treatment on NIS 
 mRNA expression by qRT-PCR 
 We treat all cell lines with ATP, EGF and the 
combination of both to induce the level of NIS mRNA 
expression. The data of NIS mRNA expression was 
calculated from the cycle threshold (CT) target toward 
CT of reference (beta-actin) and CT of control genes. 
The NIS mRNA expression fold change of treated 
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cells to untreated was analysed.  
 The expression NIS mRNA is found in 
SKBR3 and HaCaT cells but not in treated or 
untreated of MCF7 cells. The levels of NIS mRNA 
expression in SKBR3 cells after treatment by EGF, 
ATP or the combination of both for 6 and 12 hours 
were not significantly different from those of untreated 
cells. However, the treatment by a combination of 
ATP and EGF for 24 hours increases the level of NIS 
mRNA expression by 1.6fold higher than that of the 
untreated cells (1.6241 ± 0.3, p < 0.05) (Figure 1). 
Furthermore, the treatments in the HaCaT cell line do 
not change the expression of NIS mRNA in treated 
and untreated cells.  
  
Figure 1: (A) represents the effect of ATP (A); EGF (E) and a 
combination of ATP and EGF (AE) for 6, 12, 24 hours treatment of 
SKBR3 cell; The combination of ATP and EGF (AE) for 24 hours 
treatment increases NIS mRNA expression of SKBR3 cell 
significantly when compared to untreated (control) cells, P < 0.05 
 
Effect of EGF and ATP treatment on NIS 
 protein expression by 
 immunocytofluorescence 
 Results of immunocytofluorescence showed 
that NIS protein express in SKBR3 (Figure 2).  
 
Figure 2: Immunocytofluorescence staining using primary antibody 
against NIS in the SKBR3 cell line (green) and merging with DAPI 
staining (blue) at 200 x magnification. The NIS protein expression 
after 24 hours of treatments with ATP (A), EGF (B) and the 
combination of both ATP + EGF (C) and untreated (D). The 
expression of NIS protein increase both in cytoplasm and 
membrane after 24 hours of treatment by EGF and combination 
ATP + EGF (arrows) 
The NIS expression in those cells is mostly 
found in the cytoplasm. The treatments of EGF and 
the combination of both for 12 and 24 hours increase 
NIS protein expression at membrane cell twofold and 
threefold respectively, p < 0.05 (figure 2B-C). The 
cells that receive ATP only did not show increasing of 
NIS protein expression. 
Our study shows, NIS protein expression in 
HaCaT cell line only detects in the cytoplasm. 
Treatment of ATP, EGF and the combination of both 
do not induce the NIS protein expression at 
membrane cell as well as do not increase staining 
level in the cytoplasm (Figure 3). Furthermore, we 
cannot detect NIS protein expression in MCF7 cell line 
in treated and untreated cells. 
 
Figure 3: Immunocytofluorescence staining using primary antibody 
against NIS in HaCaT cell line (green) and merging with DAPI 
staining (blue) at 200 x magnification. NIS protein expression after 
24 hours of treatment by ATP (A), EGF (B) and the combination of 
both ATP and EGF (C), untreated (D). NIS protein expressions 
show only in the cytoplasm. NIS protein expressions in a treat and 
untreated cells do not have a significant different p > 0.05  
 
 
Discussion  
 
The expression of NIS in extra-thyroid tissues 
has been reported in some previous studies with 
varying intensity. These findings have been 
considered as a potential for radioiodine therapy in the 
extra-thyroid tumour, including breast cancer [4], [14], 
[15]. A study by Tazebay et al. reported that NIS was 
expressed in more than 80% of invasive breast cancer 
tissues. Another study by Wapnir et al. reported that 
the expression was found in 76% of invasive breast 
cancer tissues. Studies by other groups reported that 
34% out of 44 breast cancer tissues express NIS. 
Furthermore, they reported that 65.5% out of 23 triple-
negative breast cancer tissues expressed NIS [16], 
[17], [18], [19]. 
In this study, we find that NIS mRNA and 
protein are expressed only in SKBR3 cells, and the 
expression is not detected in MCF7 cells. Previously 
published studies on MCF7 cells reported that adding 
* 
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retinoid acid (RA) is mandatory for NIS expression 
[10], [19], [20]. Thus, it can safely be assumed that 
NIS expression in MCF7 is RA-pathway dependent. 
Till date, the molecular mechanisms of NIS 
expression in breast cancer are not clearly defined. 
Meanwhile, it is important to determine the molecular 
breast cancer subtypes which express NIS as a 
potential candidate to receive radioiodine.  
MCF7 cell line has been established as a 
breast cancer model for luminal A subtype. It has 
estrogen and progesterone receptors positive 
(ER
+
/PR
+
), HER2 receptor negative (HER2-). 
Furthermore, the SKBR3 cell line as the HER2 
subtype model with estrogen and progesterone 
receptors negative (ER
-
/PR
-
) and HER2 receptor-
positive (HER2
+
) [11], [21].
 
A study by Oh et al. 
reported that NIS expression is not correlated with the 
level of hormonal receptors, such as ER/PR. 
Hormones that regulate NIS expression in lactating 
breast stage may not play a role in breast cancer [22]. 
Moreover, a study by Dohan et al. reported 
that prolactin, oxytocin and estrogen did not induce 
NIS expression [10]. Instead, another study reported 
that NIS expresses significantly higher in ER-negative 
tumour compared to normal breast tissue [15]. Our 
finding also shows NIS expression is higher in SKBR3 
cell compare to MCF7 cell. In this condition, the 
SKBR3 cell will be appropriate to receive radioiodine 
therapy. Further studies are needed to examine the 
effectiveness of radioiodine to breast cancer based on 
subtypes.  
Besides the expression of NIS itself, 
membrane localisation of the NIS expression also 
influences radioiodine uptake by the breast cancer 
cell. The cell will be likely dependent on the level of 
functional NIS expression at the membrane cell [23]. 
In vitro study by Elliyanti et al., reported, SKBR3 cell 
showed higher uptake of radioiodine compare to 
MCF7 cell [24]. It seems, stimulating of the NIS 
expression at membrane cell is needed to increase 
radioiodine uptake. Several agents were used to 
increasing NIS expressions, such as retinoic acid, 
hormones and proliferative agents such as EGF and 
ATP [3], [9], [19], [25]. Binding of EGF with EGF 
receptor will stimulate the tyrosine kinase activity and 
will induce cell proliferation [26]. There is a correlation 
between NIS expression with cell proliferation and 
malignant transformation in human breast tissue [5], 
[6]. This leads us to hypothesise that inducing cell 
proliferation by EGF-EGFR pathway will increase NIS 
expression at the membrane. In this study, we 
observed that NIS mRNA expression and protein 
localisation at membrane cell increase by the 
combination of ATP and EGF treatment in SKBR3 
cells (Figure 2). Treatment of ATP and EGF alone do 
not increase the level of NIS mRNA; but they increase 
NIS protein expression at membrane after 12, 24 
hours of treatments. Another study reported closed to 
ours that EGF treatment augmented NIS mRNA and 
protein expression in T47D cell line, which transfected 
with NIS [9]. 
We are unable to detect NIS expression in 
treated and untreated MCF7 cell. This cell is negative 
or expresses a low level of EGF receptor [27]. This 
condition may explain the absence of NIS expression 
under EGF induction in MCF7 cells. However, EGF 
can augment NIS expression in MCF7 cells, which are 
transfected NIS, even though the cells do not have 
EGF receptors. Further studies are still required to be 
performed to elucidate the mechanism of NIS 
expression between breast cancer subtypes. 
Additionally, NIS expression was detected in 
HaCaT cell, even though the expression is within the 
cytoplasm. Neither ATP nor EGF treatments increase 
NIS expression in HaCaT cell. Interestingly, 
radioiodine was taken up by HaCaT cell, but it showed 
very minimal toxic effect compare to SKBR3 and 
MCF7 cells [24].  
In conclusion, the level of NIS expression 
varies among the different subtypes of breast cancer 
cell lines. MCF7 cell line is representing the luminal A 
subtype of breast cancer do not express NIS as well 
as SKBR3 cell line. Further studies are needed to 
cover the differences of NIS expression among breast 
cancer subtypes. It seems SKBR3 cell which 
represents the HER2 subtype of breast cancer might 
be the most suitable to receive radioiodine therapy. In 
vivo investigations are needed to prove it. 
Furthermore, a combination treatment of EGF and 
ATP in SKBR3 cell increases the expression of NIS 
mRNA and protein at membrane cells.  
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